Immunologic response to oral polio vaccine in human immunodeficiency virus-infected and uninfected Zimbabwean children

Pediatric Infectious Disease Journal

Volumn 31, Issue 2, 2012, Pages 176-180

  Gnanashanmugam, Devasena ^a,b   Troy, Stephanie B ^a,c   Musingwini, Georgina ^d   Huang, ChunHong ^a   Halpern, Meira S ^a   Stranix Chibanda, Lynda ^d   Shetty, Avinash K ^d,e   Kouiavskaia, Diana ^f   Nathoo, Kusum ^d   Chumakov, Konstantin ^f   Maldonado, Yvonne A ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pharmaceutical Product Development   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Africa; Children; HIV; OPV; Polio

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROCONVERSION; SEROTYPE; ZIMBABWE;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; POLIOMYELITIS; POLIOVIRUS VACCINE, ORAL; ZIMBABWE;

EID: 84858119904     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31823faa5f     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. Progress toward interruption of wild poliovirus transmission-worldwide, January 2010-March 2011. Morb Mortal Wkly Rep. 2011;60:582-586.
2. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec. 2010;85:213-228.
3. Grassly NC, Fraser C, Wenger J, et al. New strategies for the elimination of polio from India. Science. 2006;314:1150 -1153.
4. Global Polio Eradication Initiative: Infected Countries. Available at: http://www.polioeradication.org/Infectedcountries.aspx. Accessed May 12, 2010.
5. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine. 2009;27:2649-2652.
6. GPEI. Circulating vaccine-derived poliovirus (cVDPV) 2000-2011. Available at: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/ Circulatingvaccinederivedpoliovirus.aspx. Accessed August 9, 2011.
7. Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587- 635.
8. Jenkins H, Aylward R, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010;362:2360-2369.
9. World Health Organization. Antiretroviral therapy for infants and children. Geneva, Switzerland: World Health Organization; 2008.
10. Tejiokem MC, Gouandjika I, Beaposniguel L, et al. HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. PLoS One. 2007;2:e1260.
11. Tejiokem MC, Njamkepo E, Gouandjika I, et al. Whole-cell pertussis vaccine induces low antibody levels in human immunodeficiency virus-infected children living in sub-Saharan Africa. Clin Vaccine Immunol. 2009;16:479-483.
12. Helfand RF, Witte D, Fowlkes A, et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis. Nov 2008;198(10):1457-1465.
13. Zimbabwe Ministry of Health and Child Welfare. AIDS and TB annual report 2007. Harare, Zimbabwe: Ministry of Health; 2007.
14. WHO. Zimbabwe reported cases (vaccine-preventable diseases):. Available at: http://apps.who.int/immunization-monitoring/en/globalsummary/timeseries/ tsincidencebycountry.cfm?C=ZWE. Accessed August 10, 2011.
15. WHO. Manual for the Virological Investigation of Polio. Vol WHO/EPI/GEN/97.01. Geneva: World Health Organization (WHO); 1997.
16. Malhotra S, Lo Y-R, Nyunt MZ, et al. Management of HIV infection and antiretroviral therapy in infants and children: a clinical manual. India: World Health Organization; 2006.
17. Bernstein L, Ochs H, Wedgwood R, Rubinstein A. Defective humoral immunity in pediatric acquired immune deficiency syndrome. J Pediatr. Sep 1985;107(3):352-357. (Pubitemid 15240786)
18. Shearer W, Easley K, Goldfarb J, et al. Prospective 5-year study of peripheral blood CD4, CD8, and CD19/CD20 lymphocytes and serum Igs in children born to HIV-1 women. The P(2)C(2) HIV Study Group. J Allergy Clin Immunol. 2000;106:559-566. (Pubitemid 32037710)
19. Barbi M, Biffi M, Binda S, et al. Immunization in children with HIV seropositivity at birth: antibody response to polio vaccine and tetanus toxoid. AIDS. 1992;6:1465-1469. (Pubitemid 23011855)
20. Krasinski K, Workowsky W. Response to polio vaccination in children infected with human immunodeficiency virus [abstract]. Pediatr Res. 1987;21:328A(number 925).
21. Ryder R, Oxtoby M, Mvula M, et al. Safety and immunogenicity of bacille Calmette-Gueaposrin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr. 1993;122(5 pt 1):697-702. (Pubitemid 23134952)
22. Samoilovich E, Roivainen M, Titov LP, et al. Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children. J Med Virol. 2003;71:274 -280.
23. Maldonado Y, Peña-Cruz V, de la Luz Sanchez M, et al. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis. 1997;175:545-553.
24. Onorato IM, Modlin JF, McBean AM, et al. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis. 1991;163:1-6.
25. Barbi M, Bardare M, Luraschi C, et al. Antibody response to inactivated polio vaccine (E-IPV) in children born to HIV positive mothers. Eur J Epidemiol. 1992;8:211-216.
26. Bardare M, Barbi M, Plebani A, et al. Humoral response to inactivated poliovaccine in anti-HIV positive infants. Adv Exp Med Biol. 1989;257:221-224.
27. Blanche S, Le Deist F, Fischer A, et al. Longitudinal study of 18 children with perinatal LAV/HTLV III infection: attempt at prognostic evaluation. J Pediatr. 1986;109:965-970. (Pubitemid 17186487)
28. Kroon F, van Dissel J, Labadie J, et al. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis. 1995;21:1197-1203.
29. Vardinon N, Handsher R, Burke M, et al. Poliovirus vaccination responses in HIV-infected patients: correlation with T4 cell counts. J Infect Dis. 1990;162:238 -241.
30. Varon D, Handsher R, Dardik R, et al. Response of hemophilic patients to poliovirus vaccination: correlation with HIV serology and with immunological parameters. J Med Virol. 1993;40:91-95. (Pubitemid 23169734)
31. Newell M, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364:1236 -1243.
32. World Health Organization. Children and AIDS, fifth stocktaking report. Geneva, Switzerland: World Health Organization; 2010.
33. Sutter R, Kew O, Cochi S. Poliovirus vaccine-live. In: Paul O, Orenstein W, Plotkin S, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders/Elsevier; 2008:631- 685.
34. Modlin JF, Halsey NA, Thoms ML, et al. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J Infect Dis. 1997;175(suppl 1):S228 -S234.